Press Releases
29
Feb
2012
Genzyme Recognizes International Rare Disease Day with Second Annual Patient Advocacy Grant Program
Written by Genzyme Corporation   

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced its support of International Rare Disease Day with a series of events to celebrate and recognize the global rare disease community. Observed annually on the last day of February, Rare Disease Day seeks to call attention to rare diseases as an important public health issue, and to bring widespread recognition of increased need for education, research and treatment.

Source: Business Wire

Read more... Add new comment
 
11
Feb
2012
Amicus Therapeutics Awarded Grant From Muscular Dystrophy Association for Pompe Disease Program
Written by Amicus Therapeutics   

Funding Supports Ongoing Evaluation of AT2220 on ERT-Related Immunogenicity

CRANBURY, N.J., Feb. 7, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the receipt of a two-year, $186,000 grant from the Muscular Dystrophy Association (MDA). The grant will be used to evaluate the effect of the pharmacological chaperone AT2220 (duvoglustat HCl) on immunogenicity related to the ERT alglucosidase alfa, the only approved treatment for Pompe disease.

Source: Amicus Therapeutics, Inc.

Read more... Add new comment
 
07
Mar
2011
Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares
Written by Genzyme Corporation   

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ: GENZ) announced today that its Board of Directors unanimously recommends that Genzyme shareholders accept the sanofi-aventis revised tender offer to purchase all outstanding shares of Genzyme common stock for $74.00 and one contingent value right, per share. The Board recommends that all Genzyme shareholders tender their shares into the revised tender offer.

Source: Business Wire

Read more... Add new comment
 
08
Mar
2011
Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
Written by Amicus Therapeutics   

CRANBURY, N.J., March 8, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease. Based on data provided by Amicus, the FDA agreed with the Company's proposal to resume clinical development of AT2220, starting with a new Phase 2 study designed to evaluate the use of AT2220 when co-administered with enzyme replacement therapy (ERT) in subjects with Pompe disease. The Company expects to commence this study in the first half of 2011 and to report preliminary results in the second half of 2011.

Source: Amicus Therapeutics

Read more... Add new comment
 
01
Mar
2011
Genzyme Completes Sale of Pharmaceuticals Business to International Chemical Investors Group
Written by Genzyme Corporation   

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that it has completed the sale of its pharmaceutical intermediates business to International Chemical Investors Group (ICIG).

ICIG purchased substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion. The acquired business has been renamed Corden Pharma Switzerland LLC and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma group platform of companies. Financial terms are not material to Genzyme and were not disclosed.

Source: Business Wire

Read more... Add new comment
 
More Articles...
«StartPrev12NextEnd»

Page 1 of 2
 

Design by PacificByte